STOCK TITAN

Black Diamond (NASDAQ: BDTX) director receives 40,000 stock options at $1.71

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Black Diamond Therapeutics director Kapil Dhingra received a grant of stock options for 40,000 shares of common stock. The options have an exercise price of $1.71 per share and expire on June 25, 2036. All 40,000 options are reported as held directly following this award.

According to the grant terms, the options will vest and become exercisable in full on the earlier of June 26, 2027 or the company’s next annual meeting of stockholders, provided Dhingra continues to serve through the vesting date. This is a compensation-related award, not an open-market purchase.

Positive

  • None.

Negative

  • None.
Insider Dhingra Kapil
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 40,000 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 40,000 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Option grant size 40,000 options Stock Option (Right to Buy) awarded to director
Exercise price $1.71 per share Exercise price of stock options
Underlying shares 40,000 shares Common stock underlying the option award
Post-transaction derivative holdings 40,000 options Total derivative securities following transaction
Vesting date trigger June 26, 2027 Full vesting or earlier at next annual meeting
Expiration date June 25, 2036 Option expiration if not exercised
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
derivative security financial
"transaction_type: derivative"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
exercise price financial
"conversion_or_exercise_price: 1.7100"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"shares subject to this option shall vest and become exercisable in full"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"expiration_date: 2036-06-25T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Dhingra Kapil

(Last)(First)(Middle)
C/O BLACK DIAMOND THERAPEUTICS, INC.
ONE MAIN STREET, 14TH FLOOR

(Street)
CAMBRIDGE MASSACHUSETTS 02142

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Black Diamond Therapeutics, Inc. [ BDTX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/26/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$1.7106/26/2026A40,000 (1)06/25/2036Common Stock40,000$040,000D
Explanation of Responses:
1. The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 26, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.
/s/ Brent Hatzis-Schoch, Attorney-in-Fact06/29/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Black Diamond Therapeutics (BDTX) director Kapil Dhingra receive in this Form 4?

Kapil Dhingra received a stock option grant for 40,000 shares of Black Diamond Therapeutics common stock. The award is compensation-related, reported as a derivative security, and gives the right to buy shares at a fixed exercise price in the future.

What is the exercise price of Kapil Dhingra’s new BDTX stock options?

The stock options have an exercise price of $1.71 per share. This means Dhingra can buy up to 40,000 shares of Black Diamond Therapeutics common stock at $1.71 if and when the options vest and are exercised.

When do Kapil Dhingra’s Black Diamond Therapeutics options vest?

The options vest in full on the earlier of June 26, 2027 or Black Diamond Therapeutics’ next annual stockholder meeting. Vesting is conditioned on Dhingra’s continued service with the company through that vesting date as disclosed in the footnote.

How many Black Diamond Therapeutics options does Kapil Dhingra hold after this grant?

After this transaction, the Form 4 shows Dhingra holding 40,000 stock options. These options relate to 40,000 underlying shares of common stock and represent his position following the award reported in this specific filing.

Is Kapil Dhingra buying or selling BDTX shares in the market in this Form 4?

The Form 4 reports a grant of stock options, not an open-market trade. The transaction is coded as an acquisition (A) for 40,000 derivative securities, reflecting a compensation-related award rather than a market purchase or sale of common stock.

When do Kapil Dhingra’s Black Diamond Therapeutics options expire?

The options expire on June 25, 2036 if not exercised earlier. After that expiration date, any unexercised options become worthless, so exercise must occur after vesting and before the stated expiration to obtain common shares.